Oncotarget
AUTHOR INSIGHT, COMMUNITY NEWS & EVENTS BY ONCOTARGET:
- Targeting PCNA-Androgen Receptor Interaction Suppresses Prostate Cancer Cell Growth
A new research paper was published in Volume 16 of Oncotarget on May 20, 2025, titled “Targeting PCNA/AR interaction inhibits AR-mediated signaling in castration resistant prostate cancer cells.” - Blocking PRDX1 Protein May Improve Chemotherapy Response in Ovarian Cancer
A new research paper was published in Volume 16 of Oncotarget on May 19, 2025, titled “PRDX1 protects ATM from arsenite-induced proteotoxicity and maintains its stability during DNA damage signaling.” - Immune Side Effects of Liver Cancer Therapy Studied in Latin American PatientsA new research paper was published in Volume 16 of Oncotarget on May 19, 2025, titled “Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma.”
ABOUT DR. MIKHAIL (MISHA) BLAGOSKLONNY:
It is with great sadness and heavy heart that we announce the recent passing of Dr. Mikhail (Misha) V. Blagosklonny, our beloved Editor-in-Chief. Misha succumbed to metastatic lung cancer after a courageous battle.
Dr. Blagosklonny will be remembered as a brilliant and extraordinary scientist who dedicated his life to science. He was a visionary thinker, who made highly original contributions to cancer and aging research that were often ahead of their time.
Dr. Blagosklonny was born into a family of scientists. His mother, Professor of Medicine Yanina V. Blagosklonnaya, specialized in endocrinology and was a talented teacher, mentoring several generations of medical students. His father, Professor Vladimir M. Dilman, was a brilliant gerontologist, endocrinologist and oncologist, known for being a very charismatic person. He was the first person to encourage Misha to think about nature, aging, and philosophy.
Misha was a theorist by nature. While in school, he was deeply interested in physics and dreamed of becoming a theoretical physicist. Eventually, he chose biology, driven to study aging and age-related diseases, including cancer. He started as an experimentalist, but over the years, he became a theoretical biologist. In a way, his dream came true.
Read the full tribute to Dr. Blagosklonny | Call for Papers: Commemorative Collection Honoring Dr. Mikhail Blagosklonny | @Blagosklonny
ABOUT ONCOTARGET.NET:
Visit this page to hear from the distinguished network of authors who continue to publish their research with Oncotarget—an open access biomedical journal dedicated to publishing the latest oncology-focused, peer-reviewed research papers. Here, readers will also find information about community news and events sponsored by Oncotarget.
For the latest summaries of new and trending Oncotarget papers,visit Oncotarget.org or ImpactJournals.com. Impact Journals is Oncotarget’s academic publisher. Read about our rigorous Scientific Integrity Process.
CONTACT INFORMATION:
To get in touch with Oncotarget, please visit our website. The journal’s ISSN is 1949-2553 and is indexed and/or archived in PubMed, Scopus, PMC, and the Chan Zuckerberg Meta initiative.